✦ LIBER ✦

Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy

✍ Scribed by Karin Jordan; Iris Kinitz; Wieland Voigt; Timo Behlendorf; Hans-Heinrich Wolf; Hans-Joachim Schmoll

Book ID: 116429914
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 121 KB
Volume: 45
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2008.11.046

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiemetic efficacy and safety of a comb

Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy

✍ Hamada, Shota; Hinotsu, Shiro; Kawai, Koji; Yamada, Shigeyuki; Narita, Shintaro; 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 339 KB

Safety and efficacy of the novel antieme

Safety and efficacy of the novel antiemetic neurokinin-1 (NK-1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) – subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial

✍ J. Herrstedt; W. Arpornwirat; I. Albert; V.L. Hansen; R.R. Bandekar; J. Levin; S 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Efficacy and safety of casopitant mesyla

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

✍ Steven M Grunberg; Janusz Rolski; Janos Strausz; Zeba Aziz; Stephen Lane; Mark W 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 251 KB

The oral NK1 antagonist, aprepitant, giv

The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials

✍ R. de Wit; J. Herrstedt; B. Rapoport; A.D. Carides; J. Guoguang-Ma; M. Elmer; C. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 230 KB

Palonosetron in combination with 1-day v

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial

✍ Luigi Celio; Sergio Frustaci; Angela Denaro; Angela Buonadonna; Antonio Ardizzoi 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 185 KB

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study

✍ Albany, C.; Brames, M. J.; Fausel, C.; Johnson, C. S.; Picus, J.; Einhorn, L. H. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 156 KB